**Table S1, Histopathologic features**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| *All patients, n = 1809* | **Screening**235 (13.0%) | **Symptoms**1386 (76.6%) | **Surveillance**188 (10.4%) | **P-value** |
|  |  |  |  |  |
| T4 tumors | 14 (6.0) | 294 (21.2) | 18 (9.6) | <0.001 α γ |
| Extramural vascular invasion | 37 (15.7) | 419 (30.2) | 28 (14.9) | <0.001 α γ  |
| Lymphatic invasion | 45 (19.1) | 482 (34.8) | 47 (25.0) | <0.001 α γ |
| Perineural invasion | 22 (9.4) | 333 (24.1) | 25 (13.4) | <0.001 α γ |
| High Grade |  |  |  |  |
|  |  |  |  |  |
| *Stage I-II, n = 894* | **Screening**159 (17.8%) | **Symptoms**596 (66.7%) | **Surveillance**139 (15.5%) | **P-value** |
|  |  |  |  |  |
| T4 tumors | 3 (1.9) | 71 (11.9) | 5 (3.6) | <0.001 α γ |
| Extramural vascular invasion | 10 (6.3) | 79 (13.3) | 4 (2.9) | <0.001 α γ |
| Lymphatic invasion | 12 (7.5) | 105 (17.6) | 20 (14.4) | 0.007 α |
| Perineural invasion | 4 (2.5) | 63 (10.6) | 8 (5.8) | 0.002 α |
| High Grade | 7 (4.5) | 80 (13.6) | 14 (10.2) | 0.006 α |
|  |  |  |  |  |
| *Stage III, n = 658* | **Screening**61 (9.3%) | **Symptoms**553 (84.0%) | **Surveillance**44 (6.7%) | **P-value** |
|  |  |  |  |  |
| T4 tumors | 7 (11.5) | 102 (18.4) | 12 (27.3) | 0.112 |
| Extramural vascular invasion | 19 (31.1) | 194 (35.1) | 21 (47.7) | 0.181 |
| Lymphatic invasion | 27 (44.3) | 237 (42.9) | 24 (54.5) | 0.322 |
| Perineural invasion | 14 (23.3) | 158 (28.6) | 15 (34.1) | 0.481 |
| High Grade | 16 (26.2) | 110 (20.1) | 13 (31.0) | 0.163 |
|  |  |  |  |  |
| *Stage IV, n = 257* | **Screening**15 (5.8%) | **Symptoms**237 (92.2%) | **Surveillance**5 (1.9%) | **P-value** |
|  |  |  |  |  |
| T4 tumors | 3 (20.0) | 101 (42.6) | 1 (20.0) | 0.404 |
| Extramural vascular invasion | 8 (53.3) | 146 (61.6) | 3 (60.0) | 0.815 |
| Lymphatic invasion | 6 (40.0) | 140 (59.1) | 3 (60.0) | 0.347 |
| Perineural invasion | 4 (26.7) | 112 (47.5) | 2 (50.0) | 0.290 |
| High Grade | 4 (26.7) | 63 (26.8) | 3 (60.0) | 0.258 |
|  |  |  |  |  |
|  |  |  |  |  |

α Screening versus Symptoms P<0.05 ; β Screening versus Surveillance P<0.05 ; γ Symptoms versus Surveillance P<0.05